Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.39 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.39 |
| ▸ | CIT | O14578 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1330150 | 0.85 | BRD4 (0.49) | BRD4CITAAK1AXL | |
| SCHEMBL1328801 | 0.82 | KDM4E (0.46) | NUDT1MAP2K1CITAAK1AXL | |
| SCHEMBL1329286 | 0.81 | CDK8 (0.46) | NUDT1BRD4MAP2K1AXL | |
| SCHEMBL1329895 | 0.80 | NUDT1 (0.48) | NUDT1MAP2K1TTBK1TTBK2MET | |
| SCHEMBL12127645 | 0.78 | BRD4 (0.64) | NUDT1BRD4CIT | |
| SCHEMBL858643 | 0.77 | TTBK1 (0.46) | NUDT1BRD4MAP2K1TTBK1TTBK2 | |
| SCHEMBL1329521 | 0.76 | CCNK (0.44) | NUDT1BRD4TTBK1TTBK2MET | |
| SCHEMBL1329848 | 0.75 | AAK1 (0.52) | BRD4TTBK1TTBK2AAK1 | |
| SCHEMBL1327827 | 0.74 | BRD4 (0.48) | NUDT1BRD4MAP2K1TTBK1TTBK2 | |
| SCHEMBL1328773 | 0.74 | BRD4 (0.48) | BRD4TTBK1TTBK2METAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | claimed |
| CN-101918079-A | Protein kinase inhibitors and use thereof | MERCK SERONO SA | 2010-12-15 | — | — | CN | claimed |
| EP-2231282-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-09-29 | — | — | EP | claimed |
| WO-2009094123-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-07-30 | — | — | WO | claimed |
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP3K19, MAP3K20, MAP3K1 | NUDT1 3161/4885BRD4 1599/4885MAP2K1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.